--- title: "Artiva Biotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295139894.md" datetime: "2026-08-06T20:27:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295139894.md) - [en](https://longbridge.com/en/news/295139894.md) - [zh-HK](https://longbridge.com/zh-HK/news/295139894.md) generator: "portal-rs" --- # Artiva Biotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.63, missing the estimate of USD -0.625. EBIT: As of FY2026 Q2, the actual value is USD -25.01 M. #### Cash, Cash Equivalents and Investments As of June 30, 2026, Artiva Biotherapeutics, Inc. reported cash, cash equivalents, and investments totaling $349.4 million, which is expected to fund operations into 2029. #### Gross Proceeds from Offering In May 2026, Artiva Biotherapeutics, Inc. completed an underwritten offering of common stock and pre-funded warrants, generating gross proceeds of approximately $300 million before underwriting discounts, commissions, and offering expenses. #### Research and Development Expenses Research and development expenses for the three months ended June 30, 2026, were $21.9 million, compared to $17.9 million for the same period in 2025. For the six months ended June 30, 2026, these expenses were $41.2 million, up from $34.9 million for the six months ended June 30, 2025. #### General and Administrative Expenses General and administrative expenses were $5.0 million for the three months ended June 30, 2026, compared to $4.9 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, these expenses were $10.1 million, compared to $10.1 million for the six months ended June 30, 2025. #### Total Operating Expenses Total operating expenses for the three months ended June 30, 2026, were $26.9 million, compared to $22.8 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, total operating expenses were $51.3 million, compared to $45.0 million for the six months ended June 30, 2025. #### Loss from Operations Loss from operations for the three months ended June 30, 2026, was - $26.9 million, compared to - $22.8 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the loss from operations was - $51.3 million, compared to - $45.0 million for the six months ended June 30, 2025. #### Other Income, Net Other income, net, for the three months ended June 30, 2026, was $1.9 million, compared to $1.6 million for the same period in 2025. For the six months ended June 30, 2026, other income, net, was $2.8 million, compared to $3.4 million for the six months ended June 30, 2025. #### Net Loss Net loss totaled - $25.0 million for the three months ended June 30, 2026, compared to a net loss of - $21.3 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was - $48.5 million, compared to - $41.6 million for the six months ended June 30, 2025. Non-cash stock-based compensation expense was $1.9 million and $1.5 million for the three months ended June 30, 2026, and 2025, respectively. #### Comprehensive Loss Comprehensive loss for the three months ended June 30, 2026, was - $25.0 million, compared to - $21.3 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the comprehensive loss was - $48.6 million, compared to - $41.4 million for the six months ended June 30, 2025. #### Operational Highlights and Metrics Clinical, safety, and translational data presented at EULAR 2026 reinforced AlloNK®’s potential for B-cell depletion and clinical activity with a tolerability profile supporting outpatient administration. The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA). In the company-sponsored Phase 2a basket trial, five of seven (71%) refractory RA patients with six months of follow-up achieved an ACR50 response as of April 3, 2026. Among 55 safety-evaluable autoimmune patients treated with AlloNK plus rituximab, no cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), AlloNK-related serious adverse events, or treatment discontinuations due to adverse events were observed as of April 3, 2026. The rate of Grade 3 or higher infections was 2%, and no patients were hospitalized for infection during the initial 28-day post-treatment period. Artiva Biotherapeutics, Inc. also appointed Diego Miralles, M.D., as president and head of research and development. #### Outlook Artiva Biotherapeutics, Inc. is initiating a Phase 3 registrational randomized controlled trial for AlloNK plus rituximab in refractory RA patients in the second half of 2026. The company’s cash, cash equivalents, and investments are expected to fund operations into 2029. The FDA RMAT designation is anticipated to support the registrational strategy and provide access to expedited development and review mechanisms. ### Related Stocks - [ARTV.US](https://longbridge.com/en/quote/ARTV.US.md) ## Related News & Research - [Artiva Biotherapeutics Q2 FY26 net loss widens to $25.01 million; R&D expenses rise to $21.93 million](https://longbridge.com/en/news/295139516.md) - [RA Capital Management buys USD 456,297 of Artiva Biotherapeutics common shares](https://longbridge.com/en/news/294556883.md) - [RA Capital Management reports USD 412,776 Artiva Biotherapeutics common share purchase](https://longbridge.com/en/news/294116655.md) - [Major Investor Doubles Down on Artiva Biotherapeutics With Bold New Move](https://longbridge.com/en/news/294143110.md) - [Artiva Biotherapeutics (ARTV) to Post Earnings on Wednesday](https://longbridge.com/en/news/294211418.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**